SNTX-2643
Pharmaceutical compound
From Wikipedia, the free encyclopedia
SNTX-2643, formerly known as SENS-01, is an atypical serotonin reuptake inhibitor (SRI) derived from Sceletium tortuosum (kanna). It is under development for the treatment of social anxiety disorder, as well as other anxiety disorders and depressive disorders.[3][4][5][1][6] It is described as a novel/first-in-class and fast-acting anxiolytic with less sedation.[1][7][2][6] The drug is administered orally.[1]
- None
| Clinical data | |
|---|---|
| Other names | SNTX2643; SENS-01; SENS01 |
| Routes of administration | Oral[1] |
| Drug class | Atypical serotonin reuptake inhibitor[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Onset of action | Rapid[1][2] |
Pharmacology
SNTX-2643 acts as a selective atypical serotonin reuptake inhibitor.[1][2][6] Specifically, it binds to an allosteric site on the serotonin transporter (SERT), rather than to the orthosteric site targeted by serotonin and classical selective serotonin reuptake inhibitors (SSRIs).[1] Sceletium tortuosum (kanna) acts similarly to SNTX-2643 via its primary alkaloid constituent, mesembrine,[8] but SNTX-2643 is a synthetic derivative with improved drug-like properties.[1] Unlike SSRIs, which typically require 4–6 weeks of administration to achieve therapeutic benefits, kanna is reported to have a rapid calming effect within 30–60 minutes of ingestion.[1][2][8] The precise mechanism underlying these differences remains unclear but appears to involve distinct downstream kinase-mediated signaling pathways.[1]
Development
SNTX-2643 is being developed by Sensorium Therapeutics.[3][4][1] As of August 2025, it is undergoing phase 1 clinical trials.[1][2][9] Although listed on Psychedelic Alpha's drug development tracker, SNTX-2643 is not itself a psychedelic. Its inclusion reflects its action on the serotonin system rather than any psychedelic effects.[1][5] The chemical structure of SNTX-2643 has not yet been publicly disclosed.[3] However, mesembrine analogues acting on SERT with enhanced drug-like properties were patented by Sensorium Therapeutics in 2025.[10]